Yesterday | Dermatology Times
Glaxo's Stiefel unit to promote Amgen's Enbrel in U.S.
The Stiefel unit of GlaxoSmithKline, based here, will promote Amgen's Enbrel psoriasis treatment to U.S. dermatologists, Bloomberg News reports.
Monday | HubMed
Comparison of two etanercept regimens for treatment of psoriasis and...
OBJECTIVES: To compare the efficacy over 12 weeks of two different etanercept regimens in treating the skin manifestations of psoriasis in patients who also have psoriatic arthritis and to evaluate efficacy and safety over an additional 12 weeks of open label etanercept treatment.
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.
Tags Abstract Cytokines such as tumor necrosis factor are expressed at high levels in rheumatoid joint tissue, where they contribute significantly to inflammation and articular destruction.
Rheumatoid Arthritis Home > Questions > RA and sinus infection. RA and sinus infection.
Biomarker Could Help Doctors Tailor Treatment for Rheumatoid Arthritis
The study, led by researchers at Hospital for Special Surgery in collaboration with rheumatologists at University of Southern California, appears in the February issue of the journal Arthritis & Rheumatism.
Biomarker could help doctors tailor treatment for rheumatoid arthritis
Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor -antagonist drug.
Can you take a stimulant or appetite supressants?
Can you take a stimulant or appetite supressants? I have finally gotten my RA under control, still working on the Fibro.
Amgen reports slightly higher profit
Amgen Inc. late Monday posted a slightly higher fourth-quarter profit, its lackluster performance due largely to sluggish sales of once-hot products such as Aranesp, Neupogen and Enbrel.
NICE Draft Guidance Set To Help People With Rheumatoid Arthritis
Final draft guidance published today by the National Institute for Health and Clinical Excellence will enable another therapy to be considered for some people in England, Wales and Northern Ireland suffering with rheumatoid arthritis .
Use of Biologic Agents in the Treatment of Uveitis
These potent new agents may help some patients who are refractory to more traditional immunosuppressive therapies.
STELARA Shows Greater Efficacy Than Etanercept for Treatment of...
Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA with etanercept in the treatment of moderate to severe plaque psoriasis appear today in The New England Journal of Medicine.
Scientists put psoriasis drugs to the test
Clinical trials to test the effectiveness of two prescription drugs for the debilitating skin condition psoriasis have revealed significant differences that should help inform physicians treating patients with the condition.
Stelara Beats Enbrel in Psoriasis Study
Jan. 13, 2010 -- A recently approved drug, Stelara, is more effective than a more established drug, Enbrel, in treating moderate to severe psoriasis , according to a new study.
New Arthritis Drug Actemra Approved
Jan. 11, 2010 -- The FDA has approved Actemra for moderate to severe rheumatoid arthritis for patients who have not responded to one or more TNF inhibitors.
Do you all have good days? Brooke is tired of this now. It's time to give Enbrel a go.
Breaking the generic biotech barrier
Local companies have been rushing to develop biosimilars, the generic versions of biotech treatments.[JoongAng Ilbo] You re likely familiar with generic drugs - cheaper versions of branded chemical pharmaceuticals created by other companies after the original patent has expired.
Living With It Health Interests Drugs I am Taking I was diagnosed at age six with poly articular JRA.
UCB's Cimzia gains market share of Centocor's Simponi
BioTrends Research Group, Inc. announces the release of the final wave of LaunchTrends A : Simponi and Cimzia report.
Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates
Viron's unique drug discovery platform identifies proteins expressed by non-human viruses that have evolved over millions of years of evolutionary selection to evade their host's immune system, endowing them with powerful immuno-modulatory and anti-inflammatory properties.
I was diagnosed with RA about 5 years ago and have undergone many different therapies, from taking Aleve to Methotrexate.
Also on Topix